Evidence map›Paper›PMID 36361585›Full record

ArticleInternational journal of molecular sciences2022

Identification of Molecular Determinants in iRhoms1 and 2 That Contribute to the Substrate Selectivity of Stimulated ADAM17.

Yi Zhao, Eliud Morales Dávila, Xue Li, Beiyu Tang, Ariana I Rabinowitsch, Jose Manuel Perez-Aguilar, Carl P Blobel

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structural insights into the activation and inhibition of the ADAM17-iRhom2 complex.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yi ZhaoDepartment of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA.
Eliud Morales DávilaSchool of Chemical Sciences, Meritorious Autonomous University of Puebla (BUAP), University City, Puebla 72570, Mexico.ORCID 0000-0002-6086-4148
Xue LiDepartment of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA.
Beiyu TangDepartment of Pharmacology, Weill Cornell Medicine, New York, NY 10021, USA.
Ariana I RabinowitschDepartment of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA.
Jose Manuel Perez-AguilarSchool of Chemical Sciences, Meritorious Autonomous University of Puebla (BUAP), University City, Puebla 72570, Mexico.ORCID 0000-0002-9893-5992
Carl P BlobelDepartment of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0001-5053-3137
Cornell University · USBenemérita Universidad Autónoma de Puebla · MXHospital for Special Surgery · US

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Role of iRhoms and ADAM17 in EGFR and TNFalpha signalingR35GM134907 · NIGMS · HOSPITAL FOR SPECIAL SURGERY · PI BLOBEL, CARL PETER · 2020 to 2024
$2.0M
NIGMS NIH HHS R35 GM134907NIGMS NIH HHS T32 GM007739NIH HHS NIGMS R35 GM134907NIH HHS NIGMS T32GM007739
6 · The paper itself

Abstract

The metalloprotease ADAM17 is a key regulator of the TNFα, IL-6R and EGFR signaling pathways. The maturation and function of ADAM17 is controlled by the seven-membrane-spanning proteins iRhoms1 and 2. The functional properties of the ADAM17/iRhom1 and ADAM17/iRhom2 complexes differ, in that stimulated shedding of most ADAM17 substrates tested to date can be supported by iRhom2, whereas iRhom1 can only support stimulated shedding of very few ADAM17 substrates, such as TGFα. The first transmembrane domain (TMD1) of iRhom2 and the sole TMD of ADAM17 are important for the stimulated shedding of ADAM17 substrates by iRhom2. However, little is currently known about how the iRhoms interact with different substrates to control their stimulated shedding by ADAM17. To provide new insights into this topic, we tested how various chimeras between iRhom1 and iRhom2 affect the stimulated processing of the EGFR-ligands TGFα (iRhom1- or 2-dependent) and EREG (iRhom2-selective) by ADAM17. This uncovered an important role for the TMD7 of the iRhoms in determining their substrate selectivity. Computational methods utilized to characterize the iRhom1/2/substrate interactions suggest that the substrate selectivity is determined, at least in part, by a distinct accessibility of the substrate cleavage site to stimulated ADAM17. These studies not only provide new insights into why the substrate selectivity of stimulated iRhom2/ADAM17 differs from that of iRhom1/ADAM17, but also suggest new approaches for targeting the release of specific ADAM17 substrates.

Indexed as

Carrier ProteinsTransforming Growth Factor alphaADAM17 ProteinErbB ReceptorsMembrane ProteinsSignal TransductionADAM17 ProteinCarrier ProteinsErbB ReceptorsMembrane ProteinsTransforming Growth Factor alphaADAM17 (a disintegrin and metalloprotease 17)EGFR-ligand (epidermal growth factor receptor ligand)iRhom1 and 2 (inactive rhomboid like protein 1 and 2)protein ectodomain shedding

Identifiers

PMID36361585
PMCPMC9654401
OpenAlexW4307189929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.